Autologous Stem Cell Transplantation for Patients With AL Amyloidosis

Launched by NANJING UNIVERSITY SCHOOL OF MEDICINE · Dec 22, 2019

Keywords

ClinConnect Summary

This study is divided into two parts. In the first part, the investigators retrospectively analyze the data of patients with AL amyloidosis who treated with autologous stem cell transplantation from July 2010 to December 2019. All patients had a biopsy-proven disease by positive Congo red stain with a concomitant demonstration of plasma cell dyscrasia. Organ involvement was established according to the criteria established at the 10th International Symposium on Amyloid and Amyloidosis. The protocol of ASCT included mobilization with colony-stimulating factor alone and conditioning with high...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Male or female;
• • aged 18-75 years;
• • Patients with newly diagnosed AL;
• • Appropriate for autologous hematopoietic stem cell transplantation;
• • Abnormal M protein or free light chain detected in serum and/or urine
• • ECOG score 0-2 points;
• • Subjects (or their legal representatives) must sign an informed consent document indicating understanding the purpose of and procedures required for the study and willingness to participate in the study.
• Exclusion Criteria:
• • Pregnant and breastfeeding women;
• • Subjects suffering from multiple myeloma;
• • hypersensitivity to any treatment drugs;
• • Subjects have severe cardiovascular disease;
• • Subjects have a serious physical disease and mental illnesses;
• • Other conditions that researchers consider are not suitable for transplantation.